Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
The double-blind, U.S. Phase IIa 4429-201 trial in 72 patients with GA associated with dry AMD showed that emixustat suppressed the recovery of rod photoreceptor responses from baseline to day 14 by 2...